PMID- 35990692
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220824
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Case report: Safety and efficacy of adalimumab in treating difficult-to-treat 
      rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year 
      follow-up.
PG  - 942642
LID - 10.3389/fimmu.2022.942642 [doi]
LID - 942642
AB  - Rheumatoid arthritis (RA) is a joint-disabling inflammatory disease associated 
      with the pathology of synovitis. Some patients with RA are difficult to treat, 
      using disease-modifying anti-rheumatic drugs (DMARDs). Biology and targeted 
      synthetic DMARDs (b/tsDMARDs) are options for patients with RA. Acquired 
      immunodeficiency syndrome (AIDS) is an infectious disease caused by the human 
      immunodeficiency virus (HIV). Adalimumab is an anti-tumor necrosis factor therapy 
      commonly used in patients with RA. However, there are no reports or related data 
      on patients with RA-HIV/AIDS treated with adalimumab are available. In this 
      report, we described the first successful case of a 60-year-old HIV-positive 
      woman with difficult-to-treat RA treated with ADA after being screened for 
      hepatitis virus, latent tuberculosis (LTBI), and other infections. She contracted 
      HIV from sexual exposure while on adalimumab therapy. As the patient was 
      resistant to first-line DMARDs, she continued adalimumab along with the 
      initiation of highly active antiretroviral therapy (HAART). The patient was 
      treated with adalimumab therapy for a year; her CD4+ lymphocyte count was normal, 
      HIV-1 RNA decreased, and no new infections were triggered. The patient achieved 
      clinical remission of RA. In conclusion, adalimumab is a safe option for patients 
      with RA-HIV and may slow the progression of HIV infection. Furthermore, HAART has 
      the potential to reduce joint pain and fatigue in patients with 
      difficult-to-treat RA. CONCLUSIONS: Adalimumab is a safe option for patients with 
      RA-HIV, and may slow down the progression of HIV infection. The HAART therapy has 
      the potential to reduce joint pain and fatigue in patients with 
      difficult-to-treat RA.
CI  - Copyright (c) 2022 Chen, Deng, Zhang, Zhang, Guan and Xu.
FAU - Chen, Jing-Wen
AU  - Chen JW
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
FAU - Deng, Guo-Shu
AU  - Deng GS
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
FAU - Zhang, Wen-Shuang
AU  - Zhang WS
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
FAU - Zhang, Ming-Ying
AU  - Zhang MY
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
FAU - Guan, Tong
AU  - Guan T
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
FAU - Xu, Qiang
AU  - Xu Q
AD  - The First Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Department of Rheumatology, The First Affiliated Hospital of Guangzhou University 
      of Chinese Medicine, Guangzhou, China.
LA  - eng
PT  - Case Reports
DEP - 20220803
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antirheumatic Agents)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome/complications
MH  - Adalimumab/adverse effects
MH  - *Antirheumatic Agents/adverse effects
MH  - Arthralgia
MH  - *Arthritis, Rheumatoid/complications/diagnosis/drug therapy
MH  - Fatigue/complications
MH  - Female
MH  - Follow-Up Studies
MH  - HIV
MH  - *HIV Infections/complications/drug therapy
MH  - *HIV Seropositivity/drug therapy
MH  - Humans
MH  - Middle Aged
PMC - PMC9382239
OTO - NOTNLM
OT  - AIDS
OT  - TNF
OT  - adalimumab
OT  - human immunodeficiency virus
OT  - rheumatoid arthritis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/01/01
CRDT- 2022/08/22 03:59
PHST- 2022/05/13 00:00 [received]
PHST- 2022/07/14 00:00 [accepted]
PHST- 2022/08/22 03:59 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.942642 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 3;13:942642. doi: 10.3389/fimmu.2022.942642. eCollection 
      2022.